AbCellera Biologics

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

xr:d:DAFjWZWhAyo:2,j:5028777109,t:23051909

News

Downgrades

Price Target

Intraday Update

Markets

Analyst Ratings

Trading Ideas

ABCL

AVDX

GLOB

PGRU

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Analyst Color

Equities

Reiteration

Small Cap

General

Benchmark analyst Robert Wasserman reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ: ABCL), 

Why AbCellera Biologics Is Still A Buy Despite Dropping Royalties: Analyst On Long-Term Prospects

Penny Stocks

Movers

AAOI

AAPL

ALEC

ALHC

AMCX

AMRX

AMZN

ASRT

ATRO

ATSG

BIGC

BJDX

CARG

DKNG

DOCN

FTNT

GMBL

INVE

INVO

IRTC

KTOS

LASR

LSXMA

MCHP

MESO

MODV

NTRA

OLED

OPEN

OSUR

PANW

PRDO

RDFN

REZI

TEAM

TKAT

TMDX

TMPO

TRIN

TRUP

TWST

WISH

YELL

Gainers


	Missfresh Limited (NASDAQ: MF) jumped 168% to $1.38 after the company announced entry of share purchase agreements for financing and business acquisition.


Why ResMed Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

AbCellera Biologics Inc

Press Releases

AbCellera Reports Full Year 2024 Business Results

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

Comments

AbCellera Biologics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell